Skip to content

Efficacy of a Probiotic Lozenge (Inersan) in Patients With Chronic Periodontitis

Improvement of Periodontal Health and Reduction in Periodontal Plaque Micro-flora Using a Probiotic Lozenge in Patients With Chronic Periodontitis

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01870362
Enrollment
28
Registered
2013-06-06
Start date
2013-06-30
Completion date
2014-07-31
Last updated
2014-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Periodontitis

Brief summary

Periodontal disease is a major cause of tooth loss in humans and is one of the most prevalent diseases associated with bone loss. Following bacterial colonization, the gingiva becomes inflamed leading, in some cases, to the destruction of the alveolar bone. Periodontitis has two distinct but interconnected etiologic components, periodontopathic bacteria and host-mediated connective tissue-destructive responses to the causative bacteria and their metabolic products. A few studies have revealed that probiotic Lactobacillus strains were useful in reducing gingival inflammation and the number of black-pigmented rods, including Porphyromonas gingivalis (Pg), in the saliva and sub-gingival plaque. Concerning periodontal conditions, its shown that application of beneficial bacteria, as an adjunct to scaling and root planing (SRP), can inhibit re-colonization of pathogens in periodontal pockets and reduce bleeding on probing. The aim of the present study is to evaluate the improvement of periodontal health with probiotic (Inersan) lozenges, used as an adjunct to scaling and root planing \[SRP\].

Interventions

DRUGPlacebo

Sponsors

Mahatma Gandhi Post-Graduate Institute of Dental Sciences
CollaboratorUNKNOWN
CD Pharma India Pvt. Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
25 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Subjects of both sexes * Patients in the age group of 25-60 years * Subjects with mild to moderate chronic periodontitis, as defined by probing pocket depths 5-7mm in \> 30 % of the probing sites * The subjects should have at least 16 remaining natural teeth (minimum of at least 4 teeth per quadrant) * Subjects in good general health

Exclusion criteria

* No antibiotic therapy in the past 2 months * Medically compromised patients * Subjects who are pregnant/ lactating * Smokers and/or alcoholics. * Those who had undergone any dental surgical or non-surgical therapy within 6 months prior to the start of the study.

Design outcomes

Primary

MeasureTime frameDescription
Improvement in periodontal indices6 weeks, 12 weeksImprovement in Periodontal indices, namely, plaque index \[PI\], Gingival index \[GI\], Gingival bleeding index \[GBI\], probing pocket depth \[PPD\] and clinical attachment levels \[CAL\] in both groups

Secondary

MeasureTime frameDescription
Microbiological indices6 weeks, 12 weeksChanges in pathogen (Aggregatibacter actinomycetemcomitans (Aa), Porphyromonas gingivalis (Pg), and Prevotella intermedia) levels

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026